New strategies for managing drug spend: RA, Cancer, Hep C March 04, 2017 The proliferation of specialty drugs has prompted new techniques for keeping costs in tow. FDA approves Epclusa (sofosbuvir/velpatasvir) for chronic hepatitis C infection FDA approved EpclusaTM (sofosbuvir and velpatasvir, (SOF-VEL) for adults with chronic hepatitis C infection both with compensated cirrhosis or without cirrhosis as well as in combination with ribavirin for hepatitis C with decompensated cirrhosis. Three ways to rein in drug costs regardless of who becomes president October 13, 2016 By Marc O'Connor It’s time for stakeholders to cooperate in order to limit the wasted spending on prescription medications and chart a path to collectively improving value derivation. Insurer expands hep C drug coverage September 16, 2016 By Tracey Walker Nationwide class action suit spurs new coverage decision for hepatitis C medications. Opinion: Top 4 lessons learned from Asembia 2016 May 13, 2016 By Marc O'Connor Insights from the 2016 edition of the largest gathering in specialty pharmacy. New diagnostic tests help physicians predict HCV drug resistance May 12, 2016 By Tracey Walker Hep C virus testing supports value of diagnostics in precision medicine. FDA expands use of hep C drug February 10, 2016 By Erin Bastick FDA has approved expanded use of daclatasvir (Daklinza, Bristol-Myers Squibb) in combination with Gilead Sciences' Sovaldi (sofosbuvir), for the treatment of patients with chronic hepatitis C (HCV) genotype 1 or 3. 5 things to know about Gilead’s new hep C drug January 06, 2016 By Christine Blank Gilead Sciences, which already makes the leading hepatitis C drugs Harvoni and Sovaldi, recently received priority review from FDA for a new Hepatitis C combination drug. Watch list 2016: Top therapeutic areas November 30, 2015 Experts say you should follow these 6 therapeutic areas. J&J-Achillion partner to develop hep C drugs May 22, 2015 By Christine Blank Johnson & Johnson is expanding its reach in the lucrative hepatitis C drug market after announcing it will collaborate with Achillion Pharmaceuticals to develop its HCV drugs.